SCHEMBL1284464

SCHEMBL1284464

O=c1oc2ccccc2cc1CCl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.58
MAOB P27338 5/20 0.56
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
ADAM17 P78536 1/20 0.55
TYR P14679 1/20 0.55
DAO P14920 1/20 0.55
AKR1B1 P15121 1/20 0.55
HPGD P15428 1/20 0.55
POLB P06746 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
CA1 P00915 2/20 0.50
CA3 P07451 1/20 0.50
TSHR P16473 1/20 0.50
CA4 P22748 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27625488 0.85 MMP2 (0.67) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL13612673 0.85 MAOA (0.61) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL30594160 0.83 MAOB (0.67) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL1619109 0.83 MAOB (0.67) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL25306495 0.81 MAOA (0.58) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL765821 0.81 MAOA (0.58) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL3009674 0.81 HPGD (0.59) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL29934196 0.81 POLB (0.59) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL294595 0.81 MAOA (0.58) MAOAMAOBMMP2MMP9ADAM17
SCHEMBL1992302 0.81 MAOA (0.58) MAOAMAOBMMP2MMP9ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197910-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2009-08-06 US claimed
EP-2032541-A2 NOVEL VIRAL REPLICATION INHIBITOR Katholieke Universiteit Leuven Research & Development (BE) 2009-03-11 EP claimed
WO-2007128086-A2 NOVEL VIRAL REPLICATION INHIBITOR KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-11-15 WO claimed
WO-2018203315-A1 METHOD FOR MICROORGANISM EXTRACTION AND/OR FOR DETERMINATION OF A MICROORGANISM MAIN RESISTANCE MECHANISM AND/OR THE MINIMUM INHIBITORY CONCENTRATION OF A THERAPEUTICAL AGENT, KITS AND USES THEREOF UNIVERSIDADE DO PORTO (PT) 2018-11-08 WO disclosed
CN-102245201-B Adjuvant in immunonanotherapeutics is integrated MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-01-20 CN disclosed
US-9238712-B2 Tagged polymers and methods of use Empire Technology Developments LLC (US) 2016-01-19 US disclosed
US-20140039147-A1 TAGGED POLYMERS AND METHODS OF USE EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-02-06 US disclosed
WO-2014021892-A2 TAGGED POLYMERS AND METHODS OF USE EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-02-06 WO disclosed
US-8383843-B2 Method for preparing a coumarin compound, chromene compound, and method for preparing a chromene compound KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-26 US disclosed
US-8383843-B2 Method for preparing a coumarin compound, chromene compound, and method for preparing a chromene compound KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-26 US disclosed
US-8383843-B2 Method for preparing a coumarin compound, chromene compound, and method for preparing a chromene compound KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-26 US disclosed
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-04-12 US disclosed
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-04-12 US disclosed
US-20090197910-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2009-08-06 US disclosed
EP-2032541-A2 NOVEL VIRAL REPLICATION INHIBITOR Katholieke Universiteit Leuven Research & Development (BE) 2009-03-11 EP disclosed
WO-2007128086-A2 NOVEL VIRAL REPLICATION INHIBITOR KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-11-15 WO disclosed
US-6927283-B2 Modified acyl carrier proteins WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2005-08-09 US disclosed
US-20050118668-A1 MODIFIED ACYL CARRIER PROTEINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-02 US disclosed
US-5741662-A Direct stain specific binding assays for microorganisms QUIDEL CORPORATION (US) 1998-04-21 US disclosed
WO-1997022714-A1 DIRECT STAIN SPECIFIC BINDING ASSAYS FOR MICROORGANISMS QUIDEL CORPORATION (US) 1997-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND CYP3A7, CYP2A7, F7 MAOA 428/4885MAOB 327/4885MMP2 2719/4885
US-20090197910-A1 NOVEL VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 MAOA 2935/4885MAOB 2451/4885MMP2 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.